Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines

Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines

314486

Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines

Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to reduce the effectiveness of vaccines for COVID-19, according to a new study. “Highlighting groups who have mounted an inadequate vaccine response has already been helpful in guiding who should receive additional doses of the vaccine, and who may need to continue to take additional infection-prevention precautions over the winter,” Emma Tallantyre, co-author of the study and clinical…

You must be logged in to read/download the full post.